Hyperlipidemia: Management with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors

This article discusses PCSK9 inhibitors, their mechanism of action, indications, efficacy, safety, costs and limitations.

Source: Journal of the American Board of Family Medicine - July 9, 2018 Category: Primary Care Authors: Shahreyar, M., Salem, S. A., Nayyar, M., George, L. K., Garg, N., Koshy, S. K. G. Tags: Clinical Reviews Source Type: research